Effect of repeated glucagon doses on hepatic glycogen in type 1 Diabetes: Implications for a bihormonal Closed-Loop system

Diabetes Care

Volumn 38, Issue 11, 2015, Pages 2115-2119

  Castle, Jessica R ^a   Youssef, Joseph El ^a   Bakhtiani, Parkash A ^a   Cai, Yu ^b   Stobbe, Jade M ^b   Branigan, Deborah ^a   Ramsey, Katrina ^b   Jacobs, Peter ^c   Reddy, Ravi ^c   Woods, Mark ^b,d   Ward, W Kenneth ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d PORTLAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN; INSULIN ASPART; PIG INSULIN; RECOMBINANT GLUCAGON; GLUCAGON; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; HORMONE; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIHORMONAL CLOSED LOOP SYSTEM; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES CONTROL; DIET RESTRICTION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG SAFETY; EATING; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN SENSITIVITY; MALE; ANALYSIS; BLOOD; DEFICIENCY; DIABETES MELLITUS, TYPE 1; FEEDBACK SYSTEM; METABOLISM;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEEDBACK, PHYSIOLOGICAL; FEMALE; GLUCAGON; HORMONES; HUMANS; HYPOGLYCEMIA; INSULIN; LIVER GLYCOGEN; MALE;

EID: 84962393713     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0754     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. Peyser T, Dassau E, Breton M, Skyler JS. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci 2014;1311:102-123.
4. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-659.
5. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci 1999; 88:991-995.
6. Kadish AH. Automation control of blood sugar a servomechanism for glucose monitoring and control. Trans Am Soc Artif Intern Organs 1963;9:363-367.
7. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
8. Jacobs PG, El Youssef J, Castle J, et al. Automated control of an adaptive bihormonal, dualsensor artificial pancreas and evaluation during inpatient studies. IEEE Trans Biomed Eng 2014; 61:2569-2581.
9. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313- 325.
10. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: A randomized crossover controlled trial. CMAJ 2013;185:297-305.
11. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dualhormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015;3:17-26.
12. Castle JR, Engle JM, El Youssef J, Massoud RG, Ward WK. Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J Diabetes Sci Technol 2010;4:1305-1310.
13. Lockton JA, Poucher SM. Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge. J Pharmacol Toxicol Methods 2007;55:86-90.
14. Kishore P, Gabriely I, Cui MH, et al. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes. Diabetes 2006;55: 659-666.
15. Bischof MG, Krssak M, Krebs M, et al. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 2001; 50:392-398.
16. Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004;27:461- 467.
17. Shulman GI, Rothman DL, Chung Y, et al. 13C NMR studies of glycogen turnover in the perfused rat liver. J Biol Chem 1988;263: 5027-5029.
18. Jue T, Rothman DL, Shulman GI, Tavitian BA, DeFronzo RA, Shulman RG. Direct observation of glycogen synthesis in human muscle with 13C NMR. Proc Natl Acad Sci U S A 1989; 86:4489-4491.
19. Gruetter R, Magnusson I, Rothman DL, Avison MJ, Shulman RG, Shulman GI. Validation of 13C NMR measurements of liver glycogen in vivo. Magn Reson Med 1994;31:583-588.
20. Wolever TM. Effect of blood sampling schedule and method of calculating the area under the curve on validity and precision of glycaemic index values. Br J Nutr 2004;91: 295-301.
21. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004;25:905-920.
22. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R. Insulin kinetics in type-I diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 2005;52:3-12.
23. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996;98:378- 385.
24. Bakhtiani PA, El Youssef J, Duell AK, et al. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. J Diabetes Complications 2015;29:93-98.
25. El Youssef J, Castle JR, Bakhtiani PA, et al. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care 2014;37:3054- 3060.
26. Kropff J, Bruttomesso D, Doll W, et al. Accuracy of two continuous glucose monitoring systems: A head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab 2015;17: 343-349.
27. Jackson MA, Caputo N, Castle JR, David LL, Roberts CT Jr, Ward WK. Stable liquid glucagon formulations for rescue treatment and bihormonal closed-loop pancreas. Curr Diab Rep 2012;12:705-710.
28. Bakhtiani PA, Caputo N, Castle JR, et al. A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. J Diabetes Sci Technol 2015;9:17-23.
29. Newswanger B, Ammons S, Phadnis N, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol 2015;9: 24-33.
30. Pohl R, Li M, Krasner A, De Souza E. Development of stable liquid glucagon formulations for use in artificial pancreas. J Diabetes Sci Technol 2015;9:8-16.